Genzyme Corp. said Wednesday its leukemia treatment Clolar failed to meet its key treatment goal in a late-stage study.
The drug is already approved as a treatment for children and young adults with acute lymphoblastic leukemia, which is a cancer affecting white blood cells. The study focused on testing the drug as a potential treatment for acute myeloid leukemia in adult patients who have relapsed. That condition is a type of cancer that starts inside bone marrow.
The study, which involved 326 patients, compared Clolar in combination with chemotherapy to solely chemotherapy. The Clolar combination failed to improve overall survival rates in patients.
Despite failing the key study goal, the drug did meet some secondary goals, the company said. It doubled the overall remission rate to 47 percent.
The company said it remains committed to developing the drug for acute myeloid leukemia.
Separately, the biotechnology company reported its third-quarter net income surged on sales of Cerezyme. In midday trading, shares of the company rose 47 cents to $72.36.
**Published by "AP"
No comments:
Post a Comment